Zenotech Laboratories

Zenotech Laboratories EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of Zenotech Laboratories (532039.BO) as of Nov 22, 2026 is -149.93. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was 16.01 — a change of -1,036.68% (lower).

EV/EBITDA

-149.93

YoY

-1,036.68%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Zenotech Laboratories is 2026 -149.93 . EV/EBITDA (Enterprise Value to EBITDA) of Zenotech Laboratories was 2025 16.01 . It decreases by -1,036.68% lower compared to the previous year.

The Zenotech Laboratories EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2019
-89.44 INR
Jan 1, 2020
19.68 INR
Jan 1, 2021
47.42 INR
Jan 1, 2022
16.00 INR
Jan 1, 2023
13.06 INR
Jan 1, 2024
15.33 INR
Jan 1, 2025
16.01 INR
Jan 1, 2026
-149.93 INR
The Zenotech Laboratories EV/EBITDA history
YEAREV/EBITDAYoY
-149.93-1,036.68%
16.01+4.38%
15.33+17.45%
13.06-18.41%
16.00-66.25%
47.42+140.97%
19.68-122.00%
-89.44+173.02%
-32.76-16.57%
-39.27-10.18%
-43.72+21.99%
-35.83+104.35%
-17.54—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Zenotech Laboratories Stock analysis

What does Zenotech Laboratories do? Zenotech Laboratories Ltd manufactures and markets pharmaceutical products, specializing in oncology, biotechnology, and general injectables. The company operates from a manufacturing facility in Turkapally village, Shamirpet Mandal, Telangana, producing specialty generic injectables for the pharmaceutical sector. Its products are sold to healthcare providers and distributors within the pharmaceutical industry, targeting markets that require specialized injectable solutions. The firm's business model focuses on the production and distribution of generic injectables, leveraging its facility in Telangana to serve both domestic and international markets. By concentrating on oncology and biotechnology injectables, Zenotech addresses specific medical needs, generating revenue through the sale of these high-demand pharmaceutical products to hospitals, clinics, and pharmaceutical distributors. Zenotech Laboratories Ltd's revenue streams come from the sale of its specialty generic injectables, including oncology and biotechnology products, to healthcare institutions and distribution networks. The company's manufacturing capabilities in Telangana support its role as a supplier in the pharmaceutical supply chain, with a focus on injectable formulations that cater to critical healthcare applications. Zenotech Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Zenotech Laboratories stock

EV/EBITDA (Enterprise Value to EBITDA) of Zenotech Laboratories is -149.93 in 2026.

EV/EBITDA (Enterprise Value to EBITDA) of Zenotech Laboratories changed from 16.01 to -149.93, representing a -1,036.68% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Zenotech Laboratories since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Zenotech Laboratories with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Zenotech Laboratories

All Key Metrics — Zenotech Laboratories